Endogenous proteolytic cleavage of normal and disease-associated isoforms of the human prion protein in neural and non-neural tissues

Adolfo Jiménez-Huete, Patricia M J Lievens, Ruben Vidal, Pedro Piccardo, Bernardino Ghetti, Fabrizio Tagliavini, Blas Frangione, Frances Prelli

Research output: Contribution to journalArticle

146 Citations (Scopus)

Abstract

We have investigated the proteolytic cleavage of the cellular (PrP(c)) and pathological (PrP(Sc)) isoforms of the human prion protein (PrP) in normal and prion-affected brains and in tonsils and platelets from neurologically intact individuals. The various PrP species were resolved after deglycosylation according to their electrophoretic mobility, immunoreactivity, Sarkosyl solubility, and, as a novel approach, resistance to endogenous proteases. First, our data show that PrP(c) proteolysis in brain originates amino-truncated peptides of 21 to 22 and 18 (C1) kd that are similar in different regions and are not modified by the PrP codon 129 genotype, a polymorphism that affects the expression of prion disorders. Second, this proteolytic cleavage of PrP(c) in brain is blocked by inhibitors of metalloproteases. Third, differences in PrP(c) proteolysis, and probably in Asn glycosylation and glycosylphosphatidylinositol anchor composition, exist between neural and non-neural tissues. Fourth, protease-resistant PrP(Sc) cores in sporadic Creutzfeldt-Jakob disease (CJD) and Gerstmann- Straussler-Scheinker F198S disease brains all have an intact C1 cleavage site (Met111-His112), which precludes disruption of a domain associated with toxicity and fibrillogenesis. Fifth, the profile of endogenous proteolytic PrP(Sc) peptides is characteristic of each disorder studied, thus permitting the molecular classification of these prion diseases without the use of proteinase K and even a recognition of PrP(Sc) heterogeneity within type 2 CJD patients having different codon 129 genotype and neuropathological phenotype. This does not exclude the role of additional factors in phenotypic expression; in particular, differences in glycosylation that may be especially relevant in the new variant CJD. Proteolytic processing of PrP may play an important role in the neurotropism and phenotypic expression of prion diseases, but it does not appear to participate in disease susceptibility.

Original languageEnglish
Pages (from-to)1561-1572
Number of pages12
JournalAmerican Journal of Pathology
Volume153
Issue number5
StatePublished - Nov 1998

Fingerprint

Protein Isoforms
Creutzfeldt-Jakob Syndrome
Prion Diseases
Prions
Brain
Glycosylation
Codon
Proteolysis
Prion Proteins
Peptide Hydrolases
Gerstmann-Straussler-Scheinker Disease
Genotype
Endopeptidase K
Glycosylphosphatidylinositols
Peptides
Palatine Tonsil
Disease Susceptibility
Metalloproteases
Solubility
Blood Platelets

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Endogenous proteolytic cleavage of normal and disease-associated isoforms of the human prion protein in neural and non-neural tissues. / Jiménez-Huete, Adolfo; Lievens, Patricia M J; Vidal, Ruben; Piccardo, Pedro; Ghetti, Bernardino; Tagliavini, Fabrizio; Frangione, Blas; Prelli, Frances.

In: American Journal of Pathology, Vol. 153, No. 5, 11.1998, p. 1561-1572.

Research output: Contribution to journalArticle

Jiménez-Huete, A, Lievens, PMJ, Vidal, R, Piccardo, P, Ghetti, B, Tagliavini, F, Frangione, B & Prelli, F 1998, 'Endogenous proteolytic cleavage of normal and disease-associated isoforms of the human prion protein in neural and non-neural tissues', American Journal of Pathology, vol. 153, no. 5, pp. 1561-1572.
Jiménez-Huete, Adolfo ; Lievens, Patricia M J ; Vidal, Ruben ; Piccardo, Pedro ; Ghetti, Bernardino ; Tagliavini, Fabrizio ; Frangione, Blas ; Prelli, Frances. / Endogenous proteolytic cleavage of normal and disease-associated isoforms of the human prion protein in neural and non-neural tissues. In: American Journal of Pathology. 1998 ; Vol. 153, No. 5. pp. 1561-1572.
@article{eff700ab2d86462ebac24028291f8bcb,
title = "Endogenous proteolytic cleavage of normal and disease-associated isoforms of the human prion protein in neural and non-neural tissues",
abstract = "We have investigated the proteolytic cleavage of the cellular (PrP(c)) and pathological (PrP(Sc)) isoforms of the human prion protein (PrP) in normal and prion-affected brains and in tonsils and platelets from neurologically intact individuals. The various PrP species were resolved after deglycosylation according to their electrophoretic mobility, immunoreactivity, Sarkosyl solubility, and, as a novel approach, resistance to endogenous proteases. First, our data show that PrP(c) proteolysis in brain originates amino-truncated peptides of 21 to 22 and 18 (C1) kd that are similar in different regions and are not modified by the PrP codon 129 genotype, a polymorphism that affects the expression of prion disorders. Second, this proteolytic cleavage of PrP(c) in brain is blocked by inhibitors of metalloproteases. Third, differences in PrP(c) proteolysis, and probably in Asn glycosylation and glycosylphosphatidylinositol anchor composition, exist between neural and non-neural tissues. Fourth, protease-resistant PrP(Sc) cores in sporadic Creutzfeldt-Jakob disease (CJD) and Gerstmann- Straussler-Scheinker F198S disease brains all have an intact C1 cleavage site (Met111-His112), which precludes disruption of a domain associated with toxicity and fibrillogenesis. Fifth, the profile of endogenous proteolytic PrP(Sc) peptides is characteristic of each disorder studied, thus permitting the molecular classification of these prion diseases without the use of proteinase K and even a recognition of PrP(Sc) heterogeneity within type 2 CJD patients having different codon 129 genotype and neuropathological phenotype. This does not exclude the role of additional factors in phenotypic expression; in particular, differences in glycosylation that may be especially relevant in the new variant CJD. Proteolytic processing of PrP may play an important role in the neurotropism and phenotypic expression of prion diseases, but it does not appear to participate in disease susceptibility.",
author = "Adolfo Jim{\'e}nez-Huete and Lievens, {Patricia M J} and Ruben Vidal and Pedro Piccardo and Bernardino Ghetti and Fabrizio Tagliavini and Blas Frangione and Frances Prelli",
year = "1998",
month = "11",
language = "English",
volume = "153",
pages = "1561--1572",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Endogenous proteolytic cleavage of normal and disease-associated isoforms of the human prion protein in neural and non-neural tissues

AU - Jiménez-Huete, Adolfo

AU - Lievens, Patricia M J

AU - Vidal, Ruben

AU - Piccardo, Pedro

AU - Ghetti, Bernardino

AU - Tagliavini, Fabrizio

AU - Frangione, Blas

AU - Prelli, Frances

PY - 1998/11

Y1 - 1998/11

N2 - We have investigated the proteolytic cleavage of the cellular (PrP(c)) and pathological (PrP(Sc)) isoforms of the human prion protein (PrP) in normal and prion-affected brains and in tonsils and platelets from neurologically intact individuals. The various PrP species were resolved after deglycosylation according to their electrophoretic mobility, immunoreactivity, Sarkosyl solubility, and, as a novel approach, resistance to endogenous proteases. First, our data show that PrP(c) proteolysis in brain originates amino-truncated peptides of 21 to 22 and 18 (C1) kd that are similar in different regions and are not modified by the PrP codon 129 genotype, a polymorphism that affects the expression of prion disorders. Second, this proteolytic cleavage of PrP(c) in brain is blocked by inhibitors of metalloproteases. Third, differences in PrP(c) proteolysis, and probably in Asn glycosylation and glycosylphosphatidylinositol anchor composition, exist between neural and non-neural tissues. Fourth, protease-resistant PrP(Sc) cores in sporadic Creutzfeldt-Jakob disease (CJD) and Gerstmann- Straussler-Scheinker F198S disease brains all have an intact C1 cleavage site (Met111-His112), which precludes disruption of a domain associated with toxicity and fibrillogenesis. Fifth, the profile of endogenous proteolytic PrP(Sc) peptides is characteristic of each disorder studied, thus permitting the molecular classification of these prion diseases without the use of proteinase K and even a recognition of PrP(Sc) heterogeneity within type 2 CJD patients having different codon 129 genotype and neuropathological phenotype. This does not exclude the role of additional factors in phenotypic expression; in particular, differences in glycosylation that may be especially relevant in the new variant CJD. Proteolytic processing of PrP may play an important role in the neurotropism and phenotypic expression of prion diseases, but it does not appear to participate in disease susceptibility.

AB - We have investigated the proteolytic cleavage of the cellular (PrP(c)) and pathological (PrP(Sc)) isoforms of the human prion protein (PrP) in normal and prion-affected brains and in tonsils and platelets from neurologically intact individuals. The various PrP species were resolved after deglycosylation according to their electrophoretic mobility, immunoreactivity, Sarkosyl solubility, and, as a novel approach, resistance to endogenous proteases. First, our data show that PrP(c) proteolysis in brain originates amino-truncated peptides of 21 to 22 and 18 (C1) kd that are similar in different regions and are not modified by the PrP codon 129 genotype, a polymorphism that affects the expression of prion disorders. Second, this proteolytic cleavage of PrP(c) in brain is blocked by inhibitors of metalloproteases. Third, differences in PrP(c) proteolysis, and probably in Asn glycosylation and glycosylphosphatidylinositol anchor composition, exist between neural and non-neural tissues. Fourth, protease-resistant PrP(Sc) cores in sporadic Creutzfeldt-Jakob disease (CJD) and Gerstmann- Straussler-Scheinker F198S disease brains all have an intact C1 cleavage site (Met111-His112), which precludes disruption of a domain associated with toxicity and fibrillogenesis. Fifth, the profile of endogenous proteolytic PrP(Sc) peptides is characteristic of each disorder studied, thus permitting the molecular classification of these prion diseases without the use of proteinase K and even a recognition of PrP(Sc) heterogeneity within type 2 CJD patients having different codon 129 genotype and neuropathological phenotype. This does not exclude the role of additional factors in phenotypic expression; in particular, differences in glycosylation that may be especially relevant in the new variant CJD. Proteolytic processing of PrP may play an important role in the neurotropism and phenotypic expression of prion diseases, but it does not appear to participate in disease susceptibility.

UR - http://www.scopus.com/inward/record.url?scp=0031765769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031765769&partnerID=8YFLogxK

M3 - Article

C2 - 9811348

AN - SCOPUS:0031765769

VL - 153

SP - 1561

EP - 1572

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 5

ER -